International Psoriasis Council

Advancing Knowledge. Improving Care.

Advancing Knowledge. Improving Care.

Arthur Kavanaugh





University of California, San Diego (UCSD) School of Medicine in La Jolla
La Jolla
United States
Dr. Arthur Kavanaugh is a Professor of Medicine at the University of California, San Diego (UCSD) School of Medicine in La Jolla, CA, USA. He is also the Director of the Center for Innovative Therapy in the UCSD Division of Rheumatology, Allergy, and Immunology. Professor Kavanaugh’s main research interest has been in clinical research, particularly translational aspects of rheumatology research. This has included work delineating the pathophysiology of rheumatic diseases and defining changes associated with novel immunomodulatory therapies. Although a focus has been on rheumatoid arthritis (RA) and psoriatic arthritis (PsA), he has conducted many studies in other autoimmune conditions, including systemic lupus erythematosus, ankylosing spondylitis, inflammatory bowel disease, and others. He has been involved in helping to create guidelines for the treatment and optimal care of patients with rheumatic diseases, including RA and PsA. Professor Dr. Kavanaugh was involved in forming GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) and is currently on the executive committee. He had been a Board member of the CORRONA (Consortium of Rheumatology Researchers of North America) registry since its inception. Professor Kavanaugh has authored more than 500 peer-reviewed scientific publications and reviews, book chapters, as well as being on the editorial board of several journals. He is a fellow of the American Academy of Allergy, Asthma, and Immunology (AAAAI) and the American College of Rheumatology (ACR).
Last Updated:

Areas of Interest

Translational research focusing on PsA (biomarkers, imaging, outcomes).

Languages Spoken


Involvement with Other Organization(s)

Participates in the National Psoriasis Foundation’s (NPF) activities; previous NPF medical board member.